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c o n c i s e c o m m u n i c a t i o n
Inappropriate Use of Antifungal
Medications in a Tertiary Care Center
in Thailand: A Prospective Study
Apisada Sutepvarnon, MD;
Anucha Apisarnthanarak, MD; Bernard Camins, MD;
Kristin Mondy, MD; Victoria J. Fraser, MD
The incidence and factors associated with inappropriate use of an-
tifungal medications were studied in a Thai tertiary care center. The
incidence of inappropriate antifungal use was 74% (in 42 of 57
patients). Isolation of Candida species from urine (P p .004) was
a risk factor, whereas receipt of an infectious diseases consultation
(P p .004) was protective.
Infect Control Hosp Epidemiol 2008; 29:370-373
It is well recognized that inappropriate antifungal use con-
tributes to the global increase in antifungal resistance and
may lead to a variety of adverse outcomes, including unnec-
essary exposure to medications, persistent infections, and in-
creased costs.1 This issue has been particularly concerning in
developing countries, where antifungal management pro-
grams rarely exist. Despite these concerns, the data are limited
on the incidence and prevalence of inappropriate antifungal
use and the risk factors associated with it. We conducted a
prospective study from December 1, 2006, to June 30, 2007,
to assess the incidence of and factors associated with in-
appropriate use of antifungal medications at a hospital in
Thailand.
methods
This study was conducted at Thammasart University Hos-
pital, a 500-bed tertiary care university hospital in central
Thailand. Routine antifungal susceptibility testing is per-
formed according to Clinical and Laboratory Standards In-
stitute (CLSI) criteria.2 Both adult and pediatric infectious
diseases consultation services are readily available. There were
no existing policies for antifungal drug use at our hospital
during the study period. All hospitalized inpatients at least
15 years old who were prescribed antifungal therapy were
included. Inpatients receiving oral or intravenous antifungal
medications were monitored by the study team until dis-
charge. Each patient who received antifungal therapy was
visited 3 times: when the patient first had the antifungal ad-
ministered; when microbiologic laboratory results (ie, culture
results) were available (72 hours to 1 week after sampling,
depending on fungal pathogen); and at discharge when the
final diagnosis was available. Data were collected regarding
each patient’s demographic characteristics, comorbidities,
and Acute Physiology and Chronic Health Evaluation II
(APACHE-II) score, and the antifungal agent prescribed, in-
dication for antifungal prescription, request for infectious
diseases consultation, appropriateness of antifungal use, and
reasons for any inappropriate antifungal use. Through a re-
view of the medical records, antifungal therapy was classified
as empirical treatment for a suspected infection, prophylaxis
for fungal opportunistic infection, or treatment for a docu-
mented fungal infection. All data were collected by one in-
vestigator (A.S.) and recorded into a data collection tool. The
prescribing physicians were unaware that the study was being
performed at the time of medical chart review. The hospital’s
institutional review board approved the study.
The criteria used to define the appropriateness of antifungal
prescription were adopted from the current edition of Prin-
ciples and Practices of Infectious Diseases.3 Specific use cate-
gories were modeled after those of Kunin et al.4 and were
modified to fit local practices by an expert panel consisting
of 2 infectious diseases physicians who were not directly in-
volved in the clinical care of the study patients. Significant
candiduria was defined as a Candida concentration of at least
105 cfu/mL in a urine sample. Diagnosis of significant can-
diduria also required evidence of urinary tract pyuria (defined
as a white blood cell count of at least 10 cells/mm3, or at
least 3 white blood cells per high power field of unspun urine),
and recovery of identical Candida isolates from multiple urine
samples and/or from samples of blood and urine.5,6 Mea-
surements were performed by 2 investigators and any dis-
cordance in the assessment of appropriateness was mediated
by a third infectious diseases specialist.
Categorical variables were compared using the x2 or
Fisher’s exact test, as appropriate, and continuous variables
were compared using the Mann-Whitney U test. To evaluate
the risk factors associated with inappropriate antifungal use,
variables that were present for more than 10% of patients
and that had a P value of greater than .20 on univariate
analysis or that had a priori clinical significance were entered
into backward stepwise logistic regression models. Significant
variables that were potential covariates were grouped, and
only 1 variable from each group was chosen for entry into
the model. The final model was chosen on the basis of bi-
ological plausibility and by selecting the logistic regression
model with the lowest 2 log likelihood function. All tests
were 2-tailed, and P values less than .05 were considered to
be statistically significant.
results
During the study period, antifungal medications were pre-
scribed for 57 patients. The most common sites from which
fungus was isolated included the urine (22 [39%] of 57) and
bloodstream (17 [30%] of 57). Of the 57 patients, 47 (82%)
received antifungal medications for documented infections,
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table 1. Demographic and Clinical Characteristics of Patients Receiving











(n p 42) Pa
Age, years, median (range) 45 (15-75) 46 (22-79) .65
Female sex 10 (67) 24 (57) .52
APACHE II score, median (range) 10 (0-20) 9 (3-33) .71
Diabetes mellitus 2 (13) 14 (33) .15
Congestive heart failure 1 (7) 2 (5) .77
HIV infection 5 (33) 8 (19) .26
Chronic lung disease 1 (7) 6 (14) .44
Immunocompromised stateb 5 (33) 15 (36) .86
Fungus isolated .22
Candida albicans 5 (33) 17 (41)
Non-albicans species of Candida 4 (27) 20 (48)
Otherc 6 (40) 5 (12)
Site of isolation !.001
Urinary tract 1 (7) 21 (50)
Bloodstream 8 (53) 9 (21)
Otherd 6 (40) 12 (29)
Admission ward .68
Medicine 11 (73) 33 (79)
Surgery 3 (20) 8 (19)
Othere 1 (7) 1 (2)
Prescriber of antifungal(s) .65
Attending physician 1 (7) 3 (7)
Resident physician 3 (20) 6 (14)
Intern 11 (73) 33 (79)
Infectious diseases consultation
received 14 (100) 3 (7) !.001
note. Data are no. (%) of patients, unless otherwise noted. APACHE II, Acute
Physiology and Chronic Health Evaluation II.
a Determined by use of Fisher exact test, for proportion variables, and the Mann-
Whitney U test, for continuous variables.
b Includes patients who received chemotherapy, immunosuppressive medications, or
long-term steroid therapy (12 weeks) and neutropenic status.
c Cryptococcus neoformans and Aspergillus species.
d Respiratory tract, cerebrospinal fluid, ocular infection, and skin or wound infection;
also includes antifungal medication as prophylaxis or empirical therapy.
e Pediatrics, orthopedics, rhinootolaryngology, and obstetrics and gynecology wards.
6 (11%) received antifungals as prophylaxis, and 4 (7%) re-
ceived antifungals as empiric therapy. The overall incidence
of inappropriate antifungal use was 74% (in 42 of 57 pa-
tients). Inappropriate antifungal therapy was identified in 29
(51%) of the 57 patients at the time the antifungal was first
administered, in 31 (54%) at the time when microbiologic
laboratory results became available, and in 38 (67%) at dis-
charge. Notably, 21 (72%) of 29 patients who initially received
an inappropriate antifungal continued to receive an inappro-
priate antifungal at discharge. The most common reasons that
antifungal use was inappropriate were as follows: unnecessary
administration of antifungal agents (in 13 [31%] of 42 pa-
tients), lack of renal dose adjustment (in 12 [29%] of 42 pa-
tients), and inappropriate dose and duration (overdose or in-
adequate dose and/or inadequate or unnecessarily prolonged
duration) (in 3 [7%] of 42 patients). There was 100% agree-
ment in the assessment of antifungal use by the 2 investigators.
Seventeen (30%) of 57 patients received an infectious diseases
consultation. The proportion of patients who received an in-
fectious diseases consultation in the medical and in the surgical
services did not differ significantly (14 [32%] of 44 vs 3 [27%]
of 11; ). Table 1 compares the characteristics of patientsPp .77
who received appropriate antifungal prescriptions with those
of patients who received antifungals inappropriately, and Table
2 summarizes the incidence of and reasons for inappropriate
antifungal prescriptions.
By multivariate analysis, a urine culture positive for Can-
dida species (adjusted odds ratio [aOR], 7.1 [95% CI, 1.9-
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table 2. Incidence of and Reasons for Inappropriate Antifungal Prescriptions, Strat-
ified by Site of Fungal Isolation
Variables
No. (%) of patients, by site(s) of isolation
Any site Urine Bloodstream Othera
Inappropriate antifungal
prescription received 42 (100) 21 (50) 9 (21) 12 (29)
Admission ward
Medicine 33 (79) 16 (76) 5 (56) 12 (100)
Surgery 8 (19) 5 (24) 3 (33) …
Otherb 1 (2) … 1 (11) …
Antifungal medication
Amphotericin B 13 (31) 2 (10) 5 (56) 6 (50)
Fluconazole 27 (64) 19 (90) 4 (44) 4 (33)
Otherc 2 (5) … … 2 (17)
Reason for inappropriate prescription
Unnecessary 13 (31) 8 (38) 0 (0) 4 (33)
Lack of renal dose adjustment 12 (29) 4 (19) 6 (67) 3 (25)
Inappropriate dose and duration 3 (7) 1 (5) 2 (22) …
Otherd 14 (33) 8 (38) 1 (11) 5 (42)
a Respiratory tract, cerebrospinal fluid, ocular infection, and skin or wound infection; also includes
use of antifungal medication as prophylaxis or empirical therapy.
b Pediatrics, orthopedics, rhinootolaryngology, general practice, and obstetrics and gynecology wards.
c Itraconazole, voriconazole, or caspofungin.
d Treatment inconsistent with hospital guidelines, antifungal with too broad a spectrum, pathogen
resistant to the antifungal, patient allergic to the antifungal, and antifungal unable to penetrate to
infection site.
59.3]; ) was associated with inappropriate antifungalPp .004
use, whereas receipt of an infectious diseases consultation was
protective against inappropriate use (aOR, 0.71 [95% CI,
0.32-0.94]; ). Although the association was not sta-Pp .004
tistically significant, patients with an APACHE II score greater
than 15 were more likely to receive inappropriate antifungal
therapy than were patients with a lower score (aOR, 3.6 [95%
CI, 0.9-15.6]; ). Patients who had urine culture pos-Pp .07
itive for Candida species were more likely to have a central
venous line or a urinary catheter than were those without
such a culture result (OR, 4.5 [95% CI, 1.2-52.4]; ),Pp .01
and patients who had an APACHE II score of greater than
15 were more likely to develop renal failure during the hos-
pitalization than were those with a lower score (OR, 5.1 [95%
CI, 1.05-46.2]; ).Pp .03
discussion
Felix and colleagues7 first reported an audit of antifungal use
in a tertiary care university hospital in the United Kingdom.
The incidence of inappropriate use of antifungal medications
was 67%. The most common reasons that antifungal use was
inappropriate were inappropriate dose and duration (41%)
and inappropriate indication (27%). In Thailand, although
many studies regarding the incidence and prevalence of and
risk factors for inappropriate antibiotic use have been re-
ported,8 these studies have not examined the appropriateness
of antifungal therapy. To our knowledge, we are the first to
describe the high incidence of inappropriate antifungal use
in Thailand and emphasize the need to have an antifungal
management program.
Although the small sample size may limit our capacity to
detect other potential risk factors, our data reveal significant
associations between inappropriate antifungal use and the
isolation of fungus from the urine and a higher APACHE II
score. These associations are not surprising, because most
patients with candiduria had central line or urine catheters
placed, which led to an increase in the rate of colonization
and unnecessary treatment. Patients with a higher APACHE-
II score had been exposed to antibiotics, which led to an
increase in the rate of colonization and also a higher incidence
of renal failure requiring renal dose adjustment. Importantly,
patients who initially received inappropriate antifungal ther-
apy tended to receive inappropriate antifungal therapy
throughout their hospitalization. As has been consistently
shown in studies from developed countries,9,10 this study also
suggests the benefit of an infectious diseases consultation in
guiding appropriate antifungal use in developing countries.
Given the findings of our study, attempts to rectify the
inappropriate use of antifungal medications should be fo-
cused on educational interventions. The interventions should
include dose adjustments in patients with renal failure, im-
provement in appropriate clinical recognition of significant
candiduria, and establishment of antifungal management
programs that incorporate infectious diseases consultations.
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Further studies to evaluate factors associated with the inap-
propriate use of antifungal medications and interventions to
reduce inappropriate antifungal use in developing countries
are needed.
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